Cystic Maculopathy with Normal Capillary Permeability Secondary to Docetaxel

Teitelbaum, Bruce; Tresley, David J

doi:10.1097/00006324-200304000-00004

Cited by 74 publications

(39 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…case of macular edema associated with docetaxel use without ancillary imaging confirmation. 2 Our case is the first report, as far as the authors are aware, to document the OCT findings of CME. While CME is a D. G. Telander and D. Sarraf common cause of vision loss, the list of etiologies causing CME without FA leakage is limited, including juvenile X-linked schisis, Goldmann-Favre syndrome, and Niacin toxicity.…”

Section: Case Reportmentioning

confidence: 57%

Cystoid Macular Edema with Docetaxel Chemotherapy and the Fluid Retention Syndrome

Telander

Sarraf

2007

Seminars in Ophthalmology

View full text Add to dashboard Cite

Docetaxel (Taxotere) is an anticancer agent used to treat a wide range of malignancies including breast, lung, and prostate cancer. In this report, we describe a patient with bilateral vision loss due to cystoid macular edema (CME) associated with docetaxel therapy. This report documents for the first time the optical coherence tomography (OCT) findings of CME despite the lack of leakage with flourescein angiography and its association with the Fluid Retention Syndrome (FRS). Successful management of CME with oral acetazolamide is also discussed.

show abstract

Section: Case Reportmentioning

confidence: 57%

Cystoid Macular Edema with Docetaxel Chemotherapy and the Fluid Retention Syndrome

Telander

Sarraf

2007

Seminars in Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Their main mechanism of cytotoxic action is based on the stabilisation of microtubules leading to cell mitotic inhibition [2,3].…”

Section: Introductionmentioning

confidence: 99%

The mystery of angiographically silent macular oedema due to taxanes

Kuznetcova

Čech²,

Herbort

2012

Int Ophthalmol

View full text Add to dashboard Cite

Taxanes are widely used anticancer agents, produced from the plants of the genus Taxus (yews). One of the rare side-effects caused by taxanes is a bilateral cystoid macular oedema (CMO). The particularity of this type of CMO is that it is angiographically silent showing no leakage or pooling on fluorescein angiography (FA). To date, the mechanism of this oedema has not been clearly understood and existing theories do not explain this phenomenon very well. Our aim was to report a case of paclitaxel-induced CMO and put forward a putative explanation for this occurrence. A 64-year-old woman presented with a 7-month history of progressively decreasing bilateral visual acuity with an apparently normal fundus. At entry her best-corrected visual acuity (BCVA) was 0.4 for far and near OD and 0.5 for far and near OS. Optical coherence tomography (OCT) revealed a CMO with a central thickness of 561 μm OD and 488 μm OS; there were no signs of intraocular inflammation. FA showed no capillary leakage and quasi absent late hyperfluorescence OU. Indocyanine green angiography was within normal limits. Classical CMO treatment was ineffective and only discontinuation of paclitaxel resulted in recovery of a normal macular structure after 4 weeks with an increase of BCVA to 0.9 OD and 1.0 OS. In order to understand the properties of taxane drug-induced cystoid macular oedema (TDICMO) we compared the spectral OCT findings of our case to an inflammation-induced CMO of equal thickness and to a case of multifocal choroiditis. The plane of separation of TDICMO was above the external limiting membrane in both cases. In contrast to inflammation-induced CMO where the four external bands were well identified, there was attenuation of these bands in TDICMO but no disruption of the layers as seen in multifocal choroiditis, indicating that the fluid in TDICMO had a high viscosity producing a shadow underneath. TDICMO most probably originates from retinal pigment epithelium dysfunction by their effect on microtubule functions and not from vascular leakage. The content of the CMO seems to be made up of viscous fluid. As the origin of the CMO is not inflammatory, classical CMO treatments have no effect and only discontinuation of the taxane drug allows reversal of the CMO.

show abstract

“…In the literature, there are 13 cases of CME associated with the use of taxanes, including 6 caused by Taxol, 5 due to nanoparticle albumin-bound paclitaxel, and only 2 linked with Taxotere (docetaxel) (3,(10)(11)(12)(13)(14)(15)(16)(17). It remains an open question as to why paclitaxel is more toxic than docetaxel.…”

Section: Discussionmentioning

confidence: 99%

Cystoid macular edema secondary to paclitaxel therapy for ovarian cancer: A case report

Bassi

Loizzi

Furino

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Paclitaxel is a member of the taxane agents that has demonstrated efficacy in ovarian cancer, both in first-and in second-line therapy. Counted among the side-effects of this drug are neurological disorders. In the present study, a rare case of a non-neuropathic ocular disorder, known as cystoid macular edema (CME), due to paclitaxel in patients treated for ovarian cancer is described. Macular edema, or CME, is a common cause of visual impairment that has been classically demonstrated by fluorescein angiograms, showing capillary leakage. CME without fluorescein leakage is rare, and its most common causes are juvenile X-linked retinoschisis, Goldmann-Favre syndrome, and niacin toxicity. At the present time, the mechanism associated with the form of CME that does not exhibit any signs of fluorescein leakage has not been elucidated due to an absence of histopathological studies. Several mechanisms have been proposed, although it is considered to occur due to disruption of the normal blood-retinal barrier by molecules with a molecular weight lower than that of fluorescein, which leads to fluid accumulation in the intracellular space. It is well known that taxane agents cause fluid retention, represented by edema, weight gain, and third-space fluid collection (pericardial, pleural, ascites), and this appears to be associated with their cumulative dose. The present case study confirms that macular edema associated with paclitaxel use exhibits spontaneous resolution following discontinuation of the causative agent. Taxane-associated maculopathy has been scarcely reported in the literature, but the gynecological oncologist should be alert to its possible development, and an ophthalmologic evaluation should be offered to all patients using paclitaxel. IntroductionPaclitaxel is a member of the taxane agents that has demonstrated efficacy in ovarian cancer, both in first-and in second-line therapy (1). Neurological disorders are counted among the side-effects of this drug (2). In the present study, a rare case of a non-neuropathic ocular disorder known as cystoid macular edema (CME), due to the use of paclitaxel in patients treated for ovarian cancer, is described. Case reportIn September 2007, a 49-year-old woman underwent optimal debulking surgery for FIGO stage IIIC ovarian serious cancer, with residual disease following surgery (a tumor measuring <1 cm). The patient received adjuvant chemotherapy based on carboplatin and paclitaxel for six cycles every three weeks, achieving a complete response. The cumulative dose of paclitaxel was 1,680 mg. After 13 months, the patient presented with hepatic metastasis and peritoneal nodules. In view of the recurrence of the disease, the patient received chemotherapy based on carboplatin and pegylated liposomal doxorubicin. After 8 cycles of the chemotherapy, based on the disease progression the patient subsequently received Topotecan for 13 cycles. However, the patient then presented with pulmonary progression disease, and consequently she was treated with paclitaxel (60 m...

show abstract

Cystic Maculopathy with Normal Capillary Permeability Secondary to Docetaxel

Abstract: Docetaxel may be associated with cystic maculopathy that does not display angiographic evidence of abnormal capillary permeability.

Cited by 74 publications

References 11 publications

Cystoid Macular Edema with Docetaxel Chemotherapy and the Fluid Retention Syndrome

Cystoid Macular Edema with Docetaxel Chemotherapy and the Fluid Retention Syndrome

The mystery of angiographically silent macular oedema due to taxanes

Cystoid macular edema secondary to paclitaxel therapy for ovarian cancer: A case report

Contact Info

Product

Resources

About